108997-29-1

Basic information

• Product Name: 2-Propen-1-one, 1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-
• CAS NO: 108997-29-1
• Molecular Formula: C15H12O3
• Molecular Weight: 240.258
• Mol File: 108997-29-1.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 2-Propen-1-one, 1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propen-1-one, 1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-(108997-29-1)
• EPA Substance Registry System: 2-Propen-1-one, 1-(3-hydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-(108997-29-1)

Safety Data

• Hazardous Substances Data: 108997-29-1(Hazardous Substances Data)

Upstream product

• 121-71-1 3-Hydroxyacetophenone 
• 123-08-0 4-hydroxy-benzaldehyde 
• 5453-62-3 β-dimethylamino-m-hydroxypropiophenone hydrochloride 
• 114590-73-7 1-(3-isopropoxyphenyl)ethanone 
• 74189-56-3 4-(tetrahydropyran-2-yloxy)benzaldehyde 
• 16162-70-2 1-(3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)ethan-1-one 

Downstream Products

• 1421504-79-1 3-(5-(4-hydroxyphenyl)-4,5-dihydroisoxazol-3-yl)phenol 
• 1362510-79-9 3-[4-(4-hydroxyphenyl)-6-phenylpyridin-2-yl]phenol 
• 80816-87-1 (3-Hydroxy-phenyl)-[2-(4-hydroxy-phenyl)-cyclopropyl]-methanone 

Relevant articles and documents

Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor

We describe our rationale for designing specific catalytic inhibitors of topoisomerase II (topo II) over topoisomerase I (topo I). Based on 3D-QSAR studies of previously published dihydroxylated 2,4-diphenyl-6-aryl pyridine derivatives, 9 novel dihydroxyl

Chalcone derivatives enhance ATP-binding cassette transporters A1 in human THP-1 macrophages

Atherosclerosis is a process of imbalanced lipid metabolism in the vascular walls. The underlying pathology mainly involves the deposition of oxidized lipids in the endothelium and the accumulation of cholesterol in macrophages. Macrophages export excessive cholesterol (cholesterol efflux) through ATP-binding cassette transporter A1 (ABCA1) to counter the progression of atherosclerosis. We synthesized novel chalcone derivatives and assessed their effects and the underlying mechanisms on ABCA1 expression in macrophages. Human THP-1 macrophages were treated with synthetic chalcone derivatives for 24 h. In Western blot and flow cytometry analyses, a chalcone derivative, (E)-1-(3,4-diisopropoxyphenyl)-3-(4-isopropoxy-3-methoxyphenyl)prop- 2-en-1-one (1m), was observed to significantly enhance ABCA1 protein expression in THP-1 cells (10 μM, 24 h). Levels of mRNA of ABCA1 and liver X receptor alpha (LXRα) were quantified using a real-time quantitative polymerase chain reaction technique and were found to be significantly increased after treatment with the novel chalcone derivative 1m. Several microRNAs, including miR155, miR758, miR10b, miR145, miR33, and miR106b, which functionally inhibit ABCA1 expression were suppressed after treatment with 1m. Collectively, 1m increases ABCA1 expression in human THP-1 macrophages. The mechanisms involve the activation of the LXRα-ABCA1 pathway and suppression of certain microRNAs that regulate ABCA1 expression.

Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity

A new series of monomer and dimer derivatives of dihydroartemisinin (DHA) containing substituted chalcones as a linker were synthesized and investigated for their cytotoxicity in human cancer cell lines HL-60 (leukemia), Mia PaCa-2 (pancreatic cancer), PC

Synthesis and biological activity of 2,4-di- p -phenolyl-6- 2 -furanyl-pyridine as a potent topoisomerase II poison

Dihydroxylated 2,4-diphenyl-6-aryl pyridine derivatives were simply achieved using Claisen-Schmidt condensation reaction and modified Kr?hnke pyridine synthetic method. Total forty-five compounds were designed and synthesized which contain hydroxyl groups